↑ 薬物リストへ　← 戻る

Mt-7117 low dose    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
254ポルフィリン症2

254. ポルフィリン症　［臨床試験数：59，薬物数：52（DrugBank：17），標的遺伝子数：17，標的パスウェイ数：33］
Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 59 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04402489
(ClinicalTrials.gov)		June 1, 202020/5/2020Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked ProtoporphyriaA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked ProtoporphyriaEPP;XLPDrug: Placebo;Drug: MT-7117 Low Dose;Drug: MT-7117 High DoseMitsubishi Tanabe Pharma Development America, Inc.NULLRecruiting12 Years75 YearsAll159Phase 3United States;Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom
2NCT03520036
(ClinicalTrials.gov)		July 5, 201823/4/2018Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic ProtoporphyriaA Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic ProtoporphyriaErythropoietic Protoporphyria (EPP)Drug: MT-7117 low dose;Drug: MT-7117 high dose;Drug: PlaceboMitsubishi Tanabe Pharma Development America, Inc.NULLCompleted18 Years75 YearsAll102Phase 2United States